Clinical trials: Head and Neck Tumours
Nasopharyngeal Carcinoma, Radiation-induced Xerostomia
Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated Radiotherapy
This is a prospective phase II clinical randomized controlled study, the purpose of this study is to assess whether superficial parotid lobe-sparing intensity-modulated radiotherapy (SPLS-IMRT) can decrease the incidence of…
- Trial name
- NCT05020067
- Testing
- superficial parotid lobe-sparing intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Oropharyngeal Cancer
Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery
To evaluate the use of the daVinci Robotic System for better visibility and access of head and neck lesions and decreased amount of surgery time.
- Conditions
- Head and Neck Cancer, Oropharyngeal Cancer, Hypopharyngeal Cancer, Upper Aerodigestive Tract Neoplasms
- Trial name
- NCT00473564
- Testing
- da Vinci® Robotic System
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- University of Alabama at Birmingham
Tongue Neoplasms, Carcinoma
Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line
In vitro study to examine whether luteolin and nano-luteolin exert an inhibitory effect on tongue squamous cell carcinoma cell line by inducing apoptosis, and to assess if nano-luteolin has more efficient apoptotic activity than…
- Trial name
- NCT03288298
- Testing
- luteolin, nano-luteolin
- Volunteers
- 4 people
- Sponsor
- Cairo University
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00025298
- Testing
- amifostine trihydrate, carboplatin, cisplatin
- Where
- 13 sites in Belgium, France and 4 more
- Volunteers
- 5 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oral Squamous Cell Carcinoma, Neoadjvant Therapy
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
To evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and the CPS>10 in the biopsy samples.
- Conditions
- Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Anti-VEGFR
- Trial name
- NCT05069857
- Testing
- Camrelizumab (anti-PD-1 inhibitor), Apatinib (anti-VEGFR inhibitor)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Nasopharyngeal Carcinoma
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for nasopharyngeal carcinoma.
- Trial name
- NCT02523430
- Testing
- interventional therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Head and Neck Cancer
Central Pain Syndrome in Survivors of Head and Neck Cancer
This is a cross-sectional pilot study of head and neck cancer survivors who have completed multi-modal treatment to assess and characterize the presence of distinct pain syndromes.
- Trial name
- NCT04128267
- Testing
- IPC-1000, Magnetic resonance imaging, Correlative Studies
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Esophageal Squamous Cell Carcinoma
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus.
- Trial name
- NCT06780111
- Testing
- Pembrolizumab, I-DXd, Leucovorin
- Where
- 52 sites in United States, Brazil and 14 more
- Volunteers
- 298 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma
SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC
This is a Phase II study of anti-nectin-4 ADC combined with the EGFR monoclonal antibody and the PD-1 monoclonal antibody in participants with advanced head and neck squamous cell carcinoma.
- Trial name
- NCT06989671
- Testing
- JMT101, SYS6002, SG001
- Volunteers
- 430 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Cancer Head Neck, Metastatic Cancer
Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases
This study aims to determine the feasibility of non-invasive quantitative PD-L1 measurement using [a novel PD-L1 positron emission tomography (PET) tracer and perform immunohistochemistry based measurement of PD-L1 levels within…
- Conditions
- Cancer Head Neck, Metastatic Cancer, Metastatic Lung Cancer
- Trial name
- NCT05408871
- Testing
- adnectin 18F-BMS-986192 Head and Neck Cancer, adnectin 18F-BMS-986192 Brain Metastases
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Yale University
Esophageal Cancer
Laparoscopic Ischemic Conditioning Prior to Esophagectomy
This is a two center phase II prospective single-arm safety and feasibility trial for 20 patients with resectable esophageal carcinoma with an increased risk for anastomotic leakage, as based upon UCS and NASCET calcification…
- Trial name
- ISCON (NCT03896399)
- Testing
- Laparoscopic ischemic conditioning followed by esophagectomy
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 22 people
- Sponsor
- UMC Utrecht
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Tongue Cancer
Radiotherapy of Tongue Cancer Using an Intraoral Stent
Radiotherapy of tongue cancer is associated with acute and late morbidity. Use of an intraoral stent will provide a larger distance between the tongue and palate and can reduce side-effects.
- Trial name
- NCT04337853
- Testing
- Intraoral stent, No intraoral stent
- Where
- Norway
- Volunteers
- 13 people
- Sponsor
- Oslo University Hospital
Thyroid Nodule
Verbal Synchrony, Satisfaction and Decision-making in Face-to-face Consultations
Eligible participants will be: benign thyroid nodules patients, to be involved in a consultation with their endocrinologist and/or surgeon and/or radiologist, in order to discuss treatment options related to benign thyroid…
- Trial name
- NCT06342739
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- European Institute of Oncology
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Cancer
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00006981
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma
Esophageal cancer is a highly aggressive malignancy with a poor overall outcome. Five year survival rate after radical esophagectomy is modest at about 40%.The patients with regional lymph node metastases have worse outcome than…
- Trial name
- NCT02133612
- Testing
- paclitaxel; cisplatin
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Chinese Academy of Medical Sciences
Thyroid Neoplasms, Head and Neck Neoplasms
An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)
Doctors at the Cross Cancer Institute have developed a new method of producing 99mTc Pertechnetate in a cyclotron unit. A study done at the Cross Cancer Institute in 2011 with ten patients using this imaging agent showed that it…
- Trial name
- NCT01747512
- Testing
- C-PERT, G-PERT
- Sponsor
- AHS Cancer Control Alberta
Head and Neck Neoplasms, Skin Neoplasms
Safety Study of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Cutaneous Cancer
This study is an open, non- randomized, phase I, dose-escalating study to evaluate the safety and tolerance of Amphinex based PCI of bleomycin in patients with local recurrent or advanced/metastatic, cutaneous or sub-cutaneous…
- Trial name
- NCT00993512
- Testing
- Amphinex (TPCS2a), Bleomycin, Illumination with CeramOptec laser
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- PCI Biotech AS
Head and Neck Squamous Cell Carcinoma
FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
The goal of this FID-007 Clinical Trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- HNSCC (NCT06332092)
- Testing
- FID007
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Fulgent Pharma LLC.
Esophageal Cancer Stage III
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
Background The promising therapeutic outcomes of neoadjuvant chemoimmnotherapy in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC) have been confirmed by several phase II clinical trials and have been…
- Trial name
- NCT06965829
- Testing
- Tislelizumab, Carboplatin and Paclitaxel and Radiation Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Chest Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.